<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">22408430</PMID>
      <DateCompleted>
        <Year>2015</Year>
        <Month>09</Month>
        <Day>01</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>03</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2012</Year>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The mTOR signalling pathway in human cancer.</ArticleTitle>
        <Pagination>
          <StartPage>1886</StartPage>
          <EndPage>1918</EndPage>
          <MedlinePgn>1886-918</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms13021886</ELocationID>
        <Abstract>
          <AbstractText>The conserved serine/threonine kinase mTOR (the mammalian target of rapamycin), a downstream effector of the PI3K/AKT pathway, forms two distinct multiprotein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to rapamycin, activates S6K1 and 4EBP1, which are involved in mRNA translation. It is activated by diverse stimuli, such as growth factors, nutrients, energy and stress signals, and essential signalling pathways, such as PI3K, MAPK and AMPK, in order to control cell growth, proliferation and survival. mTORC2 is considered resistant to rapamycin and is generally insensitive to nutrients and energy signals. It activates PKC-α and AKT and regulates the actin cytoskeleton. Deregulation of multiple elements of the mTOR pathway (PI3K amplification/mutation, PTEN loss of function, AKT overexpression, and S6K1, 4EBP1 and eIF4E overexpression) has been reported in many types of cancers, particularly in melanoma, where alterations in major components of the mTOR pathway were reported to have significant effects on tumour progression. Therefore, mTOR is an appealing therapeutic target and mTOR inhibitors, including the rapamycin analogues deforolimus, everolimus and temsirolimus, are submitted to clinical trials for treating multiple cancers, alone or in combination with inhibitors of other pathways. Importantly, temsirolimus and everolimus were recently approved by the FDA for the treatment of renal cell carcinoma, PNET and giant cell astrocytoma. Small molecules that inhibit mTOR kinase activity and dual PI3K-mTOR inhibitors are also being developed. In this review, we aim to survey relevant research, the molecular mechanisms of signalling, including upstream activation and downstream effectors, and the role of mTOR in cancer, mainly in melanoma.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Pópulo</LastName>
            <ForeName>Helena</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Institute of Molecular Pathology and Immunology of University of Porto (IPATIMUP), University of Porto, 4200-465, Porto, Portugal; E-Mails:  hpopulo@ipatimup.pt  (H.P.);  jmlopes@ipatimup.pt  (J.M.L.).</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lopes</LastName>
            <ForeName>José Manuel</ForeName>
            <Initials>JM</Initials>
          </Author>
          <Author ValidYN="Y">
            <LastName>Soares</LastName>
            <ForeName>Paula</ForeName>
            <Initials>P</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2012</Year>
          <Month>02</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D046912">Multiprotein Complexes</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.1.1</RegistryNumber>
          <NameOfSubstance UI="C546842">MTOR protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076225">Mechanistic Target of Rapamycin Complex 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D058570">TOR Serine-Threonine Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048788" MajorTopicYN="N">Growth and Development</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008136" MajorTopicYN="N">Longevity</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076222" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076225" MajorTopicYN="N">Mechanistic Target of Rapamycin Complex 2</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008545" MajorTopicYN="N">Melanoma</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D046912" MajorTopicYN="N">Multiprotein Complexes</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012878" MajorTopicYN="N">Skin Neoplasms</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D058570" MajorTopicYN="N">TOR Serine-Threonine Kinases</DescriptorName>
          <QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">cancer</Keyword>
        <Keyword MajorTopicYN="N">mTOR</Keyword>
        <Keyword MajorTopicYN="N">melanoma</Keyword>
        <Keyword MajorTopicYN="N">rapamycin</Keyword>
        <Keyword MajorTopicYN="N">therapy</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2011</Year>
          <Month>12</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2012</Year>
          <Month>1</Month>
          <Day>28</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2012</Year>
          <Month>1</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2012</Year>
          <Month>3</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">22408430</ArticleId>
        <ArticleId IdType="pmc">PMC3291999</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms13021886</ArticleId>
        <ArticleId IdType="pii">ijms-13-01886</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Huang S., Houghton P.J. Targeting mTOR signaling for cancer therapy. Curr. Opin. Pharmacol. 2003;3:371–377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12901945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell. 2006;124:471–484.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16469695</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell. 2007;12:9–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17613433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heitman J., Movva N.R., Hall M.N. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253:905–909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1715094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J., Wiederrecht G., Abraham R.T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J. Biol. Chem. 1995;270:815–822.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7822316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sabatini D.M., Erdjument-Bromage H., Lui M., Tempst P., Snyder S.H. RAFT1: A mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35–43.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7518356</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown E.J., Albers M.W., Shin T.B., Ichikawa K., Keith C.T., Lane W.S., Schreiber S.L. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756–758.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8008069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Keith C.T., Schreiber S.L. PIK-related kinases: DNA repair, recombination, and cell cycle checkpoints. Science. 1995;270:50–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7569949</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kunz J., Henriquez R., Schneider U., Deuter-Reinhard M., Movva N.R., Hall M.N. Target of rapamycin in yeast, TOR2, is an essential phosphatidylinositol kinase homolog required for G1 progression. Cell. 1993;73:585–596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8387896</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou H., Huang S. The complexes of mammalian target of rapamycin. Curr. Protein Pept. Sci. 2010;11:409–424.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2928868</ArticleId>
            <ArticleId IdType="pubmed">20491627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol. Cell. 2002;10:457–468.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12408816</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov D.D., Ali S.M., Kim D.H., Guertin D.A., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr. Biol. 2004;14:1296–1302.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15268862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., Hidayat S., Tokunaga C., Avruch J., Yonezawa K. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell. 2002;110:177–189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150926</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D.H., Sarbassov D.D., Ali S.M., King J.E., Latek R.R., Erdjument-Bromage H., Tempst P., Sabatini D.M. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12150925</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sancak Y., Thoreen C.C., Peterson T.R., Lindquist R.A., Kang S.A., Spooner E., Carr S.A., Sabatini D.M. PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase. Mol. Cell. 2007;25:903–915.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17386266</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson T.R., Laplante M., Thoreen C.C., Sancak Y., Kang S.A., Kuehl W.M., Gray N.S., Sabatini D.M. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell. 2009;137:873–886.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2758791</ArticleId>
            <ArticleId IdType="pubmed">19446321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., Vasquez D.S., Turk B.E., Shaw R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell. 2008;30:214–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2674027</ArticleId>
            <ArticleId IdType="pubmed">18439900</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim D.H., Sarbassov D.D., Ali S.M., Latek R.R., Guntur K.V., Erdjument-Bromage H., Tempst P., Sabatini D.M. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol. Cell. 2003;11:895–904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12718876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guertin D.A., Stevens D.M., Thoreen C.C., Burds A.A., Kalaany N.Y., Moffat J., Brown M., Fitzgerald K.J., Sabatini D.M. Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCα, but not S6K1. Dev. Cell. 2006;11:859–871.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17141160</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng Z., Sarbassov dos D., Samudio I.J., Yee K.W., Munsell M.F., Ellen Jackson C., Giles F.J., Sabatini D.M., Andreeff M., Konopleva M. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood. 2007;109:3509–3512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1852241</ArticleId>
            <ArticleId IdType="pubmed">17179228</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 2004;18:1926–1945.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15314020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Choi J.H., Bertram P.G., Drenan R., Carvalho J., Zhou H.H., Zheng X.F. The FKBP12-rapamycin-associated protein (FRAP) is a CLIP-170 kinase. EMBO Rep. 2002;3:988–994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1307618</ArticleId>
            <ArticleId IdType="pubmed">12231510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Redpath N.T., Foulstone E.J., Proud C.G. Regulation of translation elongation factor-2 by insulin via a rapamycin-sensitive signalling pathway. EMBO J. 1996;15:2291–2297.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC450154</ArticleId>
            <ArticleId IdType="pubmed">8641294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seidel E.R., Ragan V.L. Inhibition by rapamycin of ornithine decarboxylase and epithelial cell proliferation in intestinal IEC-6 cells in culture. Br. J. Pharmacol. 1997;120:571–574.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1564498</ArticleId>
            <ArticleId IdType="pubmed">9051292</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azpiazu I., Saltiel A.R., DePaoli-Roach A.A., Lawrence J.C. Regulation of both glycogen synthase and PHAS-I by insulin in rat skeletal muscle involves mitogen-activated protein kinase-independent and rapamycin-sensitive pathways. J. Biol. Chem. 1996;271:5033–5039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8617780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudson C.C., Liu M., Chiang G.G., Otterness D.M., Loomis D.C., Kaper F., Giaccia A.J., Abraham R.T. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell Biol. 2002;22:7004–7014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC139825</ArticleId>
            <ArticleId IdType="pubmed">12242281</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huffman T.A., Mothe-Satney I., Lawrence J.C., Jr Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc. Natl. Acad. Sci. USA. 2002;99:1047–1052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC117427</ArticleId>
            <ArticleId IdType="pubmed">11792863</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parekh D., Ziegler W., Yonezawa K., Hara K., Parker P.J. Mammalian TOR controls one of two kinase pathways acting upon nPKCδ and nPKCɛ. J. Biol. Chem. 1999;274:34758–34764.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10574945</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peterson R.T., Desai B.N., Hardwick J.S., Schreiber S.L. Protein phosphatase 2A interacts with the 70-kDa S6 kinase and is activated by inhibition of FKBP12-rapamycinassociated protein. Proc. Natl. Acad. Sci. USA. 1999;96:4438–4442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC16350</ArticleId>
            <ArticleId IdType="pubmed">10200280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S., Liu L.N., Hosoi H., Dilling M.B., Shikata T., Houghton P.J. p53/p21(CIP1) cooperate in enforcing rapamycin-induced G(1) arrest and determine the cellular response to rapamycin. Cancer Res. 2001;61:3373–3381.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11309295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nourse J., Firpo E., Flanagan W.M., Coats S., Polyak K., Lee M.H., Massague J., Crabtree G.R., Roberts J.M. Interleukin-2-mediated elimination of the p27Kip1 cyclin-dependent kinase inhibitor prevented by rapamycin. Nature. 1994;372:570–573.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7990932</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Usui I., Haruta T., Iwata M., Takano A., Uno T., Kawahara J., Ueno E., Sasaoka T., Kobayashi M. Retinoblastoma protein phosphorylation via PI 3-kinase and mTOR pathway regulates adipocyte differentiation. Biochem. Biophys. Res. Commun. 2000;275:115–120.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10944451</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yokogami K., Wakisaka S., Avruch J., Reeves S.A. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr. Biol. 2000;10:47–50.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10660304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol. 2004;6:1122–1128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15467718</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frias M.A., Thoreen C.C., Jaffe J.D., Schroder W., Sculley T., Carr S.A., Sabatini D.M. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr. Biol. 2006;16:1865–1870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16919458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pearce L.R., Huang X., Boudeau J., Pawlowski R., Wullschleger S., Deak M., Ibrahim A.F., Gourlay R., Magnuson M.A., Alessi D.R. Identification of Protor as a novel Rictor-binding component of mTOR complex-2. Biochem. J. 2007;405:513–522.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2267312</ArticleId>
            <ArticleId IdType="pubmed">17461779</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin J., Masri J., Bernath A., Nishimura R.N., Gera J. Hsp70 associates with Rictor and is required for mTORC2 formation and activity. Biochem. Biophys. Res. Commun. 2008;372:578–583.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2512964</ArticleId>
            <ArticleId IdType="pubmed">18505677</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hresko R.C., Mueckler M. mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J. Biol. Chem. 2005;280:40406–40416.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16221682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 2006;22:159–168.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16603397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Um S.H., D’Alessio D., Thomas G. Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1. Cell Metab. 2006;3:393–402.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16753575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., Cohen P. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα. Curr. Biol. 1997;7:261–269.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9094314</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stokoe D., Stephens L.R., Copeland T., Gaffney P.R., Reese C.B., Painter G.F., Holmes A.B., McCormick F., Hawkins P.T. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science. 1997;277:567–570.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9228007</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–1101.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15718470</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9778245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K., Li Y., Zhu T., Wu J., Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 2002;4:648–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12172553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K., Li Y., Xu T., Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 2003;17:1829–1834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC196227</ArticleId>
            <ArticleId IdType="pubmed">12869586</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Long X., Lin Y., Ortiz-Vega S., Yonezawa K., Avruch J. Rheb binds and regulates the mTOR kinase. Curr. Biol. 2005;15:702–713.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15854902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi K., Nakagawa M., Young S.G., Yamanaka S. Differential membrane localization of ERas and Rheb, two Ras-related proteins involved in the phosphatidylinositol 3-kinase/mTOR pathway. J. Biol. Chem. 2005;280:32768–32774.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16046393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Buerger C., DeVries B., Stambolic V. Localization of Rheb to the endomembrane is critical for its signaling function. Biochem. Biophys. Res. Commun. 2006;344:869–880.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16631613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovacina K.S., Park G.Y., Bae S.S., Guzzetta A.W., Schaefer E., Birnbaum M.J., Roth R.A. Identification of a proline-rich Akt substrate as a 14-3-3 binding partner. J Biol Chem. 2003;278:10189–10194.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12524439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lim H.K., Choi Y.A., Park W., Lee T., Ryu S.H., Kim S.Y., Kim J.R., Kim J.H., Baek S.H. Phosphatidic acid regulates systemic inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 pathway. J. Biol. Chem. 2003;278:45117–45127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12960176</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nojima H., Tokunaga C., Eguchi S., Oshiro N., Hidayat S., Yoshino K., Hara K., Tanaka N., Avruch J., Yonezawa K. The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J. Biol. Chem. 2003;278:15461–15464.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12604610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalm S.S., Fingar D.C., Sabatini D.M., Blenis J. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function. Curr. Biol. 2003;13:797–806.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12747827</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalm S.S., Blenis J. Identification of a conserved motif required for mTOR signaling. Curr. Biol. 2002;12:632–639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11967149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dennis P.B., Pullen N., Kozma S.C., Thomas G. The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Mol. Cell Biol. 1996;16:6242–6251.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC231627</ArticleId>
            <ArticleId IdType="pubmed">8887654</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Faivre S., Kroemer G., Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat. Rev. Drug Discov. 2006;5:671–688.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16883305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sonenberg N., Gingras A.C. The mRNA 5′ cap-binding protein eIF4E and control of cell growth. Curr. Opin. Cell Biol. 1998;10:268–275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9561852</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pause A., Belsham G.J., Gingras A.C., Donze O., Lin T.A., Lawrence J.C., Jr, Sonenberg N. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature. 1994;371:762–767.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7935836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jastrzebski K., Hannan K.M., Tchoubrieva E.B., Hannan R.D., Pearson R.B. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors. 2007;25:209–226.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18092230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrington L.S., Findlay G.M., Gray A., Tolkacheva T., Wigfield S., Rebholz H., Barnett J., Leslie N.R., Cheng S., Shepherd P.R., et al.  The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins. J. Cell Biol. 2004;166:213–223.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2172316</ArticleId>
            <ArticleId IdType="pubmed">15249583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shah O.J., Wang Z., Hunter T. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. Curr. Biol. 2004;14:1650–1656.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15380067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning B.D., Cantley L.C. Rheb fills a GAP between TSC and TOR. Trends Biochem. Sci. 2003;28:573–576.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14607085</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., et al.  Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008;118:3065–3074.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2518073</ArticleId>
            <ArticleId IdType="pubmed">18725988</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vander Haar E., Lee S.I., Bandhakavi S., Griffin T.J., Kim D.H. Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat. Cell Biol. 2007;9:316–323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17277771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006;7:606–619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16847462</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dann S.G., Thomas G. The amino acid sensitive TOR pathway from yeast to mammals. FEBS Lett. 2006;580:2821–2829.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16684541</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kimball S.R., Jefferson L.S. Signaling pathways and molecular mechanisms through which branched-chain amino acids mediate translational control of protein synthesis. J. Nutr. 2006;136:227S–231S.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16365087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nobukuni T., Joaquin M., Roccio M., Dann S.G., Kim S.Y., Gulati P., Byfield M.P., Backer J.M., Natt F., Bos J.L., et al.  Amino acids mediate mTOR/raptor signaling through activation of class 3 phosphatidylinositol 3OH-kinase. Proc. Natl. Acad. Sci. USA. 2005;102:14238–14243.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1242323</ArticleId>
            <ArticleId IdType="pubmed">16176982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byfield M.P., Murray J.T., Backer J.M. hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J. Biol. Chem. 2005;280:33076–33082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16049009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K., Zhu T., Guan K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell. 2003;115:577–590.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14651849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hahn-Windgassen A., Nogueira V., Chen C.C., Skeen J.E., Sonenberg N., Hay N. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity. J. Biol. Chem. 2005;280:32081–32089.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16027121</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sofer A., Lei K., Johannessen C.M., Ellisen L.W. Regulation of mTOR and cell growth in response to energy stress by REDD1. Mol. Cell Biol. 2005;25:5834–5845.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1168803</ArticleId>
            <ArticleId IdType="pubmed">15988001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brugarolas J., Lei K., Hurley R.L., Manning B.D., Reiling J.H., Hafen E., Witters L.A., Ellisen L.W., Kaelin W.G., Jr Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004;18:2893–2904.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC534650</ArticleId>
            <ArticleId IdType="pubmed">15545625</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shoshani T., Faerman A., Mett I., Zelin E., Tenne T., Gorodin S., Moshel Y., Elbaz S., Budanov A., Chajut A., et al.  Identification of a novel hypoxia-inducible factor 1-responsive gene, RTP801, involved in apoptosis. Mol. Cell Biol. 2002;22:2283–2293.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC133671</ArticleId>
            <ArticleId IdType="pubmed">11884613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu L., Cash T.P., Jones R.G., Keith B., Thompson C.B., Simon M.C. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell. 2006;21:521–531.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3153113</ArticleId>
            <ArticleId IdType="pubmed">16483933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolthuis R.M., Bos J.L. Ras caught in another affair: The exchange factors for Ral. Curr. Opin. Genet. Dev. 1999;9:112–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10072355</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Repasky G.A., Chenette E.J., Der C.J. Renewing the conspiracy theory debate: Does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 2004;14:639–647.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15519853</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26:3291–3310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17496923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schubbert S., Bollag G., Shannon K. Deregulated Ras signaling in developmental disorders: New tricks for an old dog. Curr. Opin. Genet. Dev. 2007;17:15–22.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17208427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballif B.A., Roux P.P., Gerber S.A., MacKeigan J.P., Blenis J., Gygi S.P. Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc. Natl. Acad. Sci. USA. 2005;102:667–672.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC545566</ArticleId>
            <ArticleId IdType="pubmed">15647351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L., Chen Z., Erdjument-Bromage H., Tempst P., Pandolfi P.P. Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell. 2005;121:179–193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15851026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L., Teruya-Feldstein J., Bonner P., Bernardi R., Franz D.N., Witte D., Cordon-Cardo C., Pandolfi P.P. Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res. 2007;67:7106–7112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17671177</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carriere A., Ray H., Blenis J., Roux P.P. The RSK factors of activating the Ras/MAPK signaling cascade. Front. Biosci. 2008;13:4258–4275.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18508509</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyronnet S., Imataka H., Gingras A.C., Fukunaga R., Hunter T., Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 1999;18:270–279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1171121</ArticleId>
            <ArticleId IdType="pubmed">9878069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheper G.C., Morrice N.A., Kleijn M., Proud C.G. The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells. Mol. Cell Biol. 2001;21:743–754.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC86666</ArticleId>
            <ArticleId IdType="pubmed">11154262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ozes O.N., Akca H., Mayo L.D., Gustin J.A., Maehama T., Dixon J.E., Donner D.B. A phosphatidylinositol 3-kinase/Akt/mTOR pathway mediates and PTEN antagonizes tumor necrosis factor inhibition of insulin signaling through insulin receptor substrate-1. Proc. Natl. Acad. Sci. USA. 2001;98:4640–4645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC31887</ArticleId>
            <ArticleId IdType="pubmed">11287630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Glantschnig H., Fisher J.E., Wesolowski G., Rodan G.A., Reszka A.A. M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ. 2003;10:1165–1177.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14502240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee D.F., Kuo H.P., Chen C.T., Hsu J.M., Chou C.K., Wei Y., Sun H.L., Li L.Y., Ping B., Huang W.C., et al.  IKK β suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. Cell. 2007;130:440–455.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17693255</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Magnusson C., Vaux D.L. Signalling by CD95 and TNF receptors: Not only life and death. Immunol. Cell Biol. 1999;77:41–46.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10101685</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karin M. The IκB kinase—a bridge between inflammation and cancer. Cell Res. 2008;18:334–342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18301380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dan H.C., Baldwin A.S. Differential involvement of IκB kinases α and β in cytokine- and insulin-induced mammalian target of rapamycin activation determined by Akt. J. Immunol. 2008;180:7582–7589.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18490760</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 2006;127:125–137.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16962653</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J., Dibble C.C., Matsuzaki M., Manning B.D. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol. Cell Biol. 2008;28:4104–4115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2423120</ArticleId>
            <ArticleId IdType="pubmed">18411301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tremblay F., Brule S., Hee Um S., Li Y., Masuda K., Roden M., Sun X.J., Krebs M., Polakiewicz R.D., Thomas G., Marette A. Identification of IRS-1 Ser-1101 as a target of S6K1 in nutrient- and obesity-induced insulin resistance. Proc. Natl. Acad. Sci. USA. 2007;104:14056–14061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1950339</ArticleId>
            <ArticleId IdType="pubmed">17709744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oldham S., Montagne J., Radimerski T., Thomas G., Hafen E. Genetic and biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. Genes Dev. 2000;14:2689–2694.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC317036</ArticleId>
            <ArticleId IdType="pubmed">11069885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fingar D.C., Salama S., Tsou C., Harlow E., Blenis J. Mammalian cell size is controlled by mTOR and its downstream targets S6K1 and 4EBP1/eIF4E. Genes Dev. 2002;16:1472–1487.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC186342</ArticleId>
            <ArticleId IdType="pubmed">12080086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Audhya A., Loewith R., Parsons A.B., Gao L., Tabuchi M., Zhou H., Boone C., Hall M.N., Emr S.D. Genome-wide lethality screen identifies new PI4,5P2 effectors that regulate the actin cytoskeleton. EMBO J. 2004;23:3747–3757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC522789</ArticleId>
            <ArticleId IdType="pubmed">15372071</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fadri M., Daquinag A., Wang S., Xue T., Kunz J. The pleckstrin homology domain proteins Slm1 and Slm2 are required for actin cytoskeleton organization in yeast and bind phosphatidylinositol-4,5-bisphosphate and TORC2. Mol. Biol. Cell. 2005;16:1883–1900.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1073669</ArticleId>
            <ArticleId IdType="pubmed">15689497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peng T., Golub T.R., Sabatini D.M. The immunosuppressant rapamycin mimics a starvation-like signal distinct from amino acid and glucose deprivation. Mol. Cell Biol. 2002;22:5575–5584.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC133939</ArticleId>
            <ArticleId IdType="pubmed">12101249</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hannan K.M., Brandenburger Y., Jenkins A., Sharkey K., Cavanaugh A., Rothblum L., Moss T., Poortinga G., McArthur G.A., Pearson R.B., et al.  mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. Mol. Cell Biol. 2003;23:8862–8877.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC262650</ArticleId>
            <ArticleId IdType="pubmed">14612424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mayer C., Zhao J., Yuan X., Grummt I. mTOR-dependent activation of the transcription factor TIF-IA links rRNA synthesis to nutrient availability. Genes Dev. 2004;18:423–434.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC359396</ArticleId>
            <ArticleId IdType="pubmed">15004009</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kristof A.S., Marks-Konczalik J., Billings E., Moss J. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin. J. Biol. Chem. 2003;278:33637–33644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12807916</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cardenas M.E., Cutler N.S., Lorenz M.C., Di Como C.J., Heitman J. The TOR signaling cascade regulates gene expression in response to nutrients. Genes Dev. 1999;13:3271–3279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC317202</ArticleId>
            <ArticleId IdType="pubmed">10617575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hardwick J.S., Kuruvilla F.G., Tong J.K., Shamji A.F., Schreiber S.L. Rapamycin-modulated transcription defines the subset of nutrient-sensitive signaling pathways directly controlled by the Tor proteins. Proc. Natl. Acad. Sci. USA. 1999;96:14866–14870.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC24739</ArticleId>
            <ArticleId IdType="pubmed">10611304</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Powers T., Walter P. Regulation of ribosome biogenesis by the rapamycin-sensitive TOR-signaling pathway in Saccharomyces cerevisiae. Mol. Biol. Cell. 1999;10:987–1000.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC25225</ArticleId>
            <ArticleId IdType="pubmed">10198052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine B., Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2696814</ArticleId>
            <ArticleId IdType="pubmed">18191218</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizushima N., Levine B., Cuervo A.M., Klionsky D.J. Autophagy fights disease through cellular self-digestion. Nature. 2008;451:1069–1075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2670399</ArticleId>
            <ArticleId IdType="pubmed">18305538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Levine B., Klionsky D.J. Development by self-digestion: Molecular mechanisms and biological functions of autophagy. Dev. Cell. 2004;6:463–477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15068787</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu H., Yang J.M., Jin S., Zhang H., Hait W.N. Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer Res. 2006;66:3015–3023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16540650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu L., McPhee C.K., Zheng L., Mardones G.A., Rong Y., Peng J., Mi N., Zhao Y., Liu Z., Wan F., et al.  Termination of autophagy and reformation of lysosomes regulated by mTOR. Nature. 2010;465:942–946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2920749</ArticleId>
            <ArticleId IdType="pubmed">20526321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tee A.R., Blenis J. mTOR, translational control and human disease. Semin. Cell Dev. Biol. 2005;16:29–37.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15659337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas G.V., Horvath S., Smith B.L., Crosby K., Lebel L.A., Schrage M., Said J., de Kernion J., Reiter R.E., Sawyers C.L. Antibody-based profiling of the phosphoinositide 3-kinase pathway in clinical prostate cancer. Clin. Cancer Res. 2004;10:8351–8356.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15623612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim J.E., Chen J. regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis. Diabetes. 2004;53:2748–2756.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15504954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lazar M.A. PPAR gamma, 10 years later. Biochimie. 2005;87:9–13.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15733730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Um S.H., Frigerio F., Watanabe M., Picard F., Joaquin M., Sticker M., Fumagalli S., Allegrini P.R., Kozma S.C., Auwerx J., Thomas G. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature. 2004;431:200–205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15306821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martin D.E., Hall M.N. The expanding TOR signaling network. Curr. Opin. Cell Biol. 2005;17:158–166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15780592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colman R.J., Anderson R.M., Johnson S.C., Kastman E.K., Kosmatka K.J., Beasley T.M., Allison D.B., Cruzen C., Simmons H.A., Kemnitz J.W., et al.  Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325:201–204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2812811</ArticleId>
            <ArticleId IdType="pubmed">19590001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrison D.E., Strong R., Sharp Z.D., Nelson J.F., Astle C.M., Flurkey K., Nadon N.L., Wilkinson J.E., Frenkel K., Carter C.S., et al.  Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009;460:392–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2786175</ArticleId>
            <ArticleId IdType="pubmed">19587680</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21376230</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sato T., Nakashima A., Guo L., Coffman K., Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene. 2010;29:2746–2752.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2953941</ArticleId>
            <ArticleId IdType="pubmed">20190810</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou B.P., Hu M.C., Miller S.A., Yu Z., Xia W., Lin S.Y., Hung M.C. HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J. Biol. Chem. 2000;275:8027–8031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10713122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chung J., Bachelder R.E., Lipscomb E.A., Shaw L.M., Mercurio A.M. Integrin (α6β4) regulation of eIF-4E activity and VEGF translation: A survival mechanism for carcinoma cells. J. Cell Biol. 2002;158:165–174.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2173018</ArticleId>
            <ArticleId IdType="pubmed">12105188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., Neve R.M., Kuo W.L., Davies M., Carey M., Hu Z., Guan Y., Sahin A., et al.  An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 2008;68:6084–6091.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2680495</ArticleId>
            <ArticleId IdType="pubmed">18676830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sansal I., Sellers W.R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J. Clin. Oncol. 2004;22:2954–2963.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15254063</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tamguney T., Stokoe D. New insights into PTEN. J. Cell Sci. 2007;120:4071–4079.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18032782</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2002;2:489–501.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12094235</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Armengol G., Rojo F., Castellvi J., Iglesias C., Cuatrecasas M., Pons B., Baselga J., Ramon y Cajal S. 4E-binding protein 1: A key molecular “funnel factor” in human cancer with clinical implications. Cancer Res. 2007;67:7551–7555.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17699757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coleman L.J., Peter M.B., Teall T.J., Brannan R.A., Hanby A.M., Honarpisheh H., Shaaban A.M., Smith L., Speirs V., Verghese E.T., et al.  Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br. J. Cancer. 2009;100:1393–1399.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2694424</ArticleId>
            <ArticleId IdType="pubmed">19367274</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>No J.H., Jeon Y.T., Park I.A., Kim Y.B., Kim J.W., Park N.H., Kang S.B., Han J.Y., Lim J.M., Song Y.S. Activation of mTOR signaling pathway associated with adverse prognostic factors of epithelial ovarian cancer. Gynecol. Oncol. 2011;121:8–12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21276607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bjornsti M.A., Houghton P.J. Lost in translation: Dysregulation of cap-dependent translation and cancer. Cancer Cell. 2004;5:519–523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15193254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ruggero D., Montanaro L., Ma L., Xu W., Londei P., Cordon-Cardo C., Pandolfi P.P. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat. Med. 2004;10:484–486.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15098029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., Puc J., Miliaresis C., Rodgers L., McCombie R., et al.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997;275:1943–1947.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9072974</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Campbell I.G., Russell S.E., Choong D.Y., Montgomery K.G., Ciavarella M.L., Hooi C.S., Cristiano B.E., Pearson R.B., Phillips W.A. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 2004;64:7678–7681.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15520168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006;441:424–430.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16724053</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Basso A.D., Mirza A., Liu G., Long B.J., Bishop W.R., Kirschmeier P. The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity. J. Biol. Chem. 2005;280:31101–31108.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16006564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu Z.H., Shvartsman M.B., Lee A.Y., Shao J.M., Murray M.M., Kladney R.D., Fan D., Krajewski S., Chiang G.G., Mills G.B., et al.  Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res. 2010;70:3287–3298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2855737</ArticleId>
            <ArticleId IdType="pubmed">20388784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barlund M., Forozan F., Kononen J., Bubendorf L., Chen Y., Bittner M.L., Torhorst J., Haas P., Bucher C., Sauter G., et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. J. Natl. Cancer Inst. 2000;92:1252–1259.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10922410</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Populo H., Soares P., Faustino A., Rocha A.S., Silva P., Azevedo F., Lopes J.M. mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics. Pigment Cell Melanoma Res. 2011;24:254–257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21029395</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hiramatsu M., Ninomiya H., Inamura K., Nomura K., Takeuchi K., Satoh Y., Okumura S., Nakagawa K., Yamori T., Matsuura M., et al.  Activation status of receptor tyrosine kinase downstream pathways in primary lung adenocarcinoma with reference of KRAS and EGFR mutations. Lung Cancer. 2010;70:94–102.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20117855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noh W.C., Kim Y.H., Kim M.S., Koh J.S., Kim H.A., Moon N.M., Paik N.S. Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables. Breast Cancer Res. Treat. 2008;110:477–483.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17805960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pantuck A.J., Seligson D.B., Klatte T., Yu H., Leppert J.T., Moore L., O’Toole T., Gibbons J., Belldegrun A.S., Figlin R.A. Prognostic relevance of the mTOR pathway in renal cell carcinoma: Implications for molecular patient selection for targeted therapy. Cancer. 2007;109:2257–2267.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17440983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou L., Huang Y., Li J., Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med. Oncol. 2010;27:255–261.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19301157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K., Corradetti M.N., Guan K.L. Dysregulation of the TSC-mTOR pathway in human disease. Nat. Genet. 2005;37:19–24.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15624019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vignot S., Faivre S., Aguirre D., Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann. Oncol. 2005;16:525–537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15728109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hager M., Haufe H., Kemmerling R., Mikuz G., Kolbitsch C., Moser P.L. PTEN expression in renal cell carcinoma and oncocytoma and prognosis. Pathology. 2007;39:482–485.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17886097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madhunapantula S.V., Robertson G.P. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 2009;22:400–419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3610526</ArticleId>
            <ArticleId IdType="pubmed">19493313</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson S.R., Tattersfield A.E. Lymphangioleiomyomatosis. Semin. Respir. Crit. Care Med. 2002;23:85–92.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16088601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwiatkowski D.J. Tuberous sclerosis: From tubers to mTOR. Ann. Hum. Genet. 2003;67:87–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12556239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning B.D., Cantley L.C. United at last: The tuberous sclerosis complex gene products connect the phosphoinositide 3-kinase/Akt pathway to mammalian target of rapamycin (mTOR) signalling. Biochem. Soc. Trans. 2003;31:573–578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12773158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Benedetti A., Graff J.R. eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004;23:3189–3199.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15094768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura J.L., Garcia E., Pieper R.O. S6K1 plays a key role in glial transformation. Cancer Res. 2008;68:6516–6523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2538583</ArticleId>
            <ArticleId IdType="pubmed">18701474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liaw D., Marsh D.J., Li J., Dahia P.L., Wang S.I., Zheng Z., Bose S., Call K.M., Tsou H.C., Peacocke M., et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 1997;16:64–67.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9140396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaw R.J., Bardeesy N., Manning B.D., Lopez L., Kosmatka M., DePinho R.A., Cantley L.C. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6:91–99.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15261145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johannessen C.M., Reczek E.E., James M.F., Brems H., Legius E., Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc. Natl. Acad. Sci. USA. 2005;102:8573–8578.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1142482</ArticleId>
            <ArticleId IdType="pubmed">15937108</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dahl C., Guldberg P. The genome and epigenome of malignant melanoma. Apmis. 2007;115:1161–1176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18042149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dai D.L., Martinka M., Li G. Prognostic significance of activated Akt expression in melanoma: A clinicopathologic study of 292 cases. J. Clin. Oncol. 2005;23:1473–1482.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15735123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu H., Goel V., Haluska F.G. PTEN signaling pathways in melanoma. Oncogene. 2003;22:3113–3122.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12789288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reifenberger J., Wolter M., Bostrom J., Buschges R., Schulte K.W., Megahed M., Ruzicka T., Reifenberger G. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch. 2000;436:487–493.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10881743</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Celebi J.T., Shendrik I., Silvers D.N., Peacocke M. Identification of PTEN mutations in metastatic melanoma specimens. J. Med. Genet. 2000;37:653–657.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC1734683</ArticleId>
            <ArticleId IdType="pubmed">10978354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsao H., Zhang X., Fowlkes K., Haluska F.G. Relative reciprocity of NRAS and PTEN/MMAC1 alterations in cutaneous melanoma cell lines. Cancer Res. 2000;60:1800–1804.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10766161</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsao H., Goel V., Wu H., Yang G., Haluska F.G. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 2004;122:337–341.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2586668</ArticleId>
            <ArticleId IdType="pubmed">15009714</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davies M.A., Stemke-Hale K., Tellez C., Calderone T.L., Deng W., Prieto V.G., Lazar A.J., Gershenwald J.E., Mills G.B. A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer. 2008;99:1265–1268.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2570525</ArticleId>
            <ArticleId IdType="pubmed">18813315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dhawan P., Singh A.B., Ellis D.L., Richmond A. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-κB and tumor progression. Cancer Res. 2002;62:7335–7342.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12499277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stahl J.M., Sharma A., Cheung M., Zimmerman M., Cheng J.Q., Bosenberg M.W., Kester M., Sandirasegarane L., Robertson G.P. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 2004;64:7002–7010.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15466193</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meier F., Schittek B., Busch S., Garbe C., Smalley K., Satyamoorthy K., Li G., Herlyn M. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. 2005;10:2986–3001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15970553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cheung M., Sharma A., Madhunapantula S.V., Robertson G.P. Akt3 and mutant V600EB-Raf cooperate to promote early melanoma development. Cancer Res. 2008;68:3429–3439.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2603082</ArticleId>
            <ArticleId IdType="pubmed">18451171</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Madhunapantula S.V., Sharma A., Robertson G.P. PRAS40 deregulates apoptosis in malignant melanoma. Cancer Res. 2007;67:3626–3636.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17440074</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Saraiva V.S., Caissie A.L., Segal L., Edelstein C., Burnier M.N., Jr Immunohistochemical expression of phospho-Akt in uveal melanoma. Melanoma Res. 2005;15:245–250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16034301</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Populo H., Soares P., Rocha A.S., Silva P., Lopes J.M. Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma. Melanoma Res. 2010;20:107–117.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20173664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdel-Rahman M.H., Yang Y., Zhou X.P., Craig E.L., Davidorf F.H., Eng C. High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma. J. Clin. Oncol. 2006;24:288–295.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16344319</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Smalley K.S., Eisen T.G. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int. J. Cancer. 2003;105:165–175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12673674</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Easton J.B., Houghton P.J. mTOR and cancer therapy. Oncogene. 2006;25:6436–6446.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17041628</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vezina C., Kudelski A., Sehgal S.N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J. Antibiot. (Tokyo) 1975;28:721–726.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1102508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eng C.P., Sehgal S.N., Vezina C. Activity of rapamycin (AY-22,989) against transplanted tumors. J. Antibiot. (Tokyo) 1984;37:1231–1237.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">6501094</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Linhares M.M., Gonzalez A.M., Trivino T., Melaragno C., Moura R.M., Garcez M.H., Sa J.R., Aguiar W.F., Succi T., Barbosa C.S., et al.  Simultaneous pancreas-kidney transplantation initial experience. Transplant. Proc. 2003;35:1109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12947878</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang S., Houghton P.J. Resistance to rapamycin: A novel anticancer drug. Cancer Metastasis Rev. 2001;20:69–78.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11831650</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dilling M.B., Dias P., Shapiro D.N., Germain G.S., Johnson R.K., Houghton P.J. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 1994;54:903–907.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7508822</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Geoerger B., Kerr K., Tang C.B., Fung K.M., Powell B., Sutton L.N., Phillips P.C., Janss A.J. Antitumor activity of the rapamycin analog CCI-779 in human primitive neuroectodermal tumor/medulloblastoma models as single agent and in combination chemotherapy. Cancer Res. 2001;61:1527–1532.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11245461</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seufferlein T., Rozengurt E. Rapamycin inhibits constitutive p70s6k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 1996;56:3895–3897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8752154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawa T., Tokuda M., Tomizawa K., Matsui H., Itano T., Konishi R., Nagahata S., Hatase O. Osteoblastic differentiation is enhanced by rapamycin in rat osteoblast-like osteosarcoma (ROS 17/2.8) cells. Biochem. Biophys. Res. Commun. 1998;249:226–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9705862</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grewe M., Gansauge F., Schmid R.M., Adler G., Seufferlein T. Regulation of cell growth and cyclin D1 expression by the constitutively active FRAP-p70s6K pathway in human pancreatic cancer cells. Cancer Res. 1999;59:3581–3587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">10446965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pang H., Faber L.E. Estrogen and rapamycin effects on cell cycle progression in T47D breast cancer cells. Breast Cancer Res. Treat. 2001;70:21–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11767001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Poel H.G., Hanrahan C., Zhong H., Simons J.W. Rapamycin induces Smad activity in prostate cancer cell lines. Urol. Res. 2003;30:380–386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12599018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muthukkumar S., Ramesh T.M., Bondada S. Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. Transplantation. 1995;60:264–270.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7544036</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Phung T.L., Ziv K., Dabydeen D., Eyiah-Mensah G., Riveros M., Perruzzi C., Sun J., Monahan-Earley R.A., Shiojima I., Nagy J.A., et al.  Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell. 2006;10:159–170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2531257</ArticleId>
            <ArticleId IdType="pubmed">16904613</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas G.V., Tran C., Mellinghoff I.K., Welsbie D.S., Chan E., Fueger B., Czernin J., Sawyers C.L. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat. Med. 2006;12:122–127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16341243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gingras A.C., Raught B., Gygi S.P., Niedzwiecka A., Miron M., Burley S.K., Polakiewicz R.D., Wyslouch-Cieszynska A., Aebersold R., Sonenberg N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev. 2001;15:2852–2864.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC312813</ArticleId>
            <ArticleId IdType="pubmed">11691836</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dumont F.J., Su Q. Mechanism of action of the immunosuppressant rapamycin. Life Sci. 1996;58:373–395.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8594303</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dancey J.E. Therapeutic targets: MTOR and related pathways. Cancer Biol. Ther. 2006;5:1065–1073.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16969122</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rini B.I. Temsirolimus, an inhibitor of mammalian target of rapamycin. Clin. Cancer Res. 2008;14:1286–1290.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18316545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rizzieri D.A., Feldman E., Dipersio J.F., Gabrail N., Stock W., Strair R., Rivera V.M., Albitar M., Bedrosian C.L., Giles F.J. A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2008;14:2756–2762.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18451242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wolpin B.M., Hezel A.F., Abrams T., Blaszkowsky L.S., Meyerhardt J.A., Chan J.A., Enzinger P.C., Allen B., Clark J.W., Ryan D.P., et al.  Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J. Clin. Oncol. 2009;27:193–198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2645085</ArticleId>
            <ArticleId IdType="pubmed">19047305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnston P.B., Inwards D.J., Colgan J.P., Laplant B.R., Kabat B.F., Habermann T.M., Micallef I.N., Porrata L.F., Ansell S.M., Reeder C.B., et al.  A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. Am. J. Hematol. 2010;85:320–324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4420736</ArticleId>
            <ArticleId IdType="pubmed">20229590</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Witzig T.E., Reeder C.B., LaPlant B.R., Gupta M., Johnston P.B., Micallef I.N., Porrata L.F., Ansell S.M., Colgan J.P., Jacobsen E.D., et al.  A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25:341–347.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3049870</ArticleId>
            <ArticleId IdType="pubmed">21135857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ellard S.L., Clemons M., Gelmon K.A., Norris B., Kennecke H., Chia S., Pritchard K., Eisen A., Vandenberg T., Taylor M., et al.  Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J. Clin. Oncol. 2009;27:4536–4541.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19687332</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oza A.M., Elit L., Tsao M.S., Kamel-Reid S., Biagi J., Provencher D.M., Gotlieb W.H., Hoskins P.J., Ghatage P., Tonkin K.S., et al.  Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: A trial of the NCIC Clinical Trials Group. J. Clin. Oncol. 2011;29:3278–3285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3158598</ArticleId>
            <ArticleId IdType="pubmed">21788564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hess G., Herbrecht R., Romaguera J., Verhoef G., Crump M., Gisselbrecht C., Laurell A., Offner F., Strahs A., Berkenblit A., et al.  Phase III study to evaluate temsirolimus compared with investigator’s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J. Clin. Oncol. 2009;27:3822–389.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19581539</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>O’Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006;66:1500–1508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3193604</ArticleId>
            <ArticleId IdType="pubmed">16452206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Del Bufalo D., Ciuffreda L., Trisciuoglio D., Desideri M., Cognetti F., Zupi G., Milella M. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res. 2006;66:5549–5554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">16740688</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gossage L., Eisen T. Alterations in VHL as potential biomarkers in renal-cell carcinoma. Nat. Rev. Clin. Oncol. 2010;7:277–288.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20368728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feldman M.E., Apsel B., Uotila A., Loewith R., Knight Z.A., Ruggero D., Shokat K.M. Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2. PLoS Biol. 2009;7:e38.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2637922</ArticleId>
            <ArticleId IdType="pubmed">19209957</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thoreen C.C., Kang S.A., Chang J.W., Liu Q., Zhang J., Gao Y., Reichling L.J., Sim T., Sabatini D.M., Gray N.S. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009;284:8023–8032.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2658096</ArticleId>
            <ArticleId IdType="pubmed">19150980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Molckovsky A., Siu L.L. First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol. 2008;1:20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2647552</ArticleId>
            <ArticleId IdType="pubmed">18959794</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yap T.A., Garrett M.D., Walton M.I., Raynaud F., de Bono J.S., Workman P. Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr. Opin. Pharmacol. 2008;8:393–412.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18721898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu T.J., Koul D., LaFortune T., Tiao N., Shen R.J., Maira S.M., Garcia-Echevrria C., Yung W.K. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol. Cancer Ther. 2009;8:2204–2210.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2752877</ArticleId>
            <ArticleId IdType="pubmed">19671762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballou L.M., Lin R.Z. Rapamycin and mTOR kinase inhibitors. J. Chem. Biol. 2008;1:27–36.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2698317</ArticleId>
            <ArticleId IdType="pubmed">19568796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chresta C.M., Davies B.R., Hickson I., Harding T., Cosulich S., Critchlow S.E., Vincent J.P., Ellston R., Jones D., Sini P., et al.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity. Cancer Res. 2010;70:288–298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20028854</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garcia-Martinez J.M., Moran J., Clarke R.G., Gray A., Cosulich S.C., Chresta C.M., Alessi D.R. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) Biochem. J. 2009;421:29–42.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2708931</ArticleId>
            <ArticleId IdType="pubmed">19402821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu K., Toral-Barza L., Shi C., Zhang W.G., Lucas J., Shor B., Kim J., Verheijen J., Curran K., Malwitz D.J., et al.  Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res. 2009;69:6232–6240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19584280</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raynaud F.I., Eccles S., Clarke P.A., Hayes A., Nutley B., Alix S., Henley A., Di-Stefano F., Ahmad Z., Guillard S., et al.  Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res. 2007;67:5840–5850.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17575152</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatesan A.M., Chen Z., dos Santos O., Dehnhardt C., Santos E.D., Ayral-Kaloustian S., Mallon R., Hollander I., Feldberg L., Lucas J., et al.  PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor. Bioorg. Med. Chem. Lett. 2010;20:5869–5873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20797855</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Venkatesan A.M., Dehnhardt C.M., Delos Santos E., Chen Z., Dos Santos O., Ayral-Kaloustian S., Khafizova G., Brooijmans N., Mallon R., Hollander I., et al.  Bis(morpholino-1,3,5-triazine) derivatives: Potent adenosine 5′-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: Discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor. J. Med. Chem. 2010;53:2636–2645.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20166697</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grunwald V., DeGraffenried L., Russel D., Friedrichs W.E., Ray R.B., Hidalgo M. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells. Cancer Res. 2002;62:6141–6145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12414639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mondesire W.H., Jian W., Zhang H., Ensor J., Hung M.C., Mills G.B., Meric-Bernstam F. Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. 2004;10:7031–7042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15501983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Steelman L.S., Navolanic P.M., Sokolosky M.L., Taylor J.R., Lehmann B.D., Chappell W.H., Abrams S.L., Wong E.W., Stadelman K.M., Terrian D.M., et al.  Suppression of PTEN function increases breast cancer chemotherapeutic drug resistance while conferring sensitivity to mTOR inhibitors. Oncogene. 2008;27:4086–4095.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3836277</ArticleId>
            <ArticleId IdType="pubmed">18332865</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreisl T.N., Lassman A.B., Mischel P.S., Rosen N., Scher H.I., Teruya-Feldstein J., Shaffer D., Lis E., Abrey L.E. A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) J. Neurooncol. 2009;92:99–105.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19018475</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reardon D.A., Desjardins A., Vredenburgh J.J., Gururangan S., Friedman A.H., Herndon J.E., 2nd, Marcello J., Norfleet J.A., McLendon R.E., Sampson J.H., et al.  Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J. Neurooncol. 2010;96:219–230.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2844073</ArticleId>
            <ArticleId IdType="pubmed">19562254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnston S.R. New strategies in estrogen receptor-positive breast cancer. Clin. Cancer Res. 2010;16:1979–1987.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20332324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Morrow P.K., Wulf G.M., Ensor J., Booser D.J., Moore J.A., Flores P.R., Xiong Y., Zhang S., Krop I.E., Winer E.P., et al.  Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J. Clin. Oncol. 2011;29:3126–3132.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3157979</ArticleId>
            <ArticleId IdType="pubmed">21730275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merchan J.R., Pitot H.C., Qin R., Liu G., Fitch T.R., Picus J., Maples W.J., Erlichman C. Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma (RCC): Safety and activity in RTKI refractory RCC patients. J. Clin. Oncol. 2009;27 abstract 5039.</Citation>
        </Reference>
        <Reference>
          <Citation>Patnaik A., Ricart A., Cooper J., Papadopoulos K., Beeram M., Mita C., Mita M.M., Hufnagel D., Izbicka E., Tolcher A.W. A phase I, pharmacokinetic and pharmacodynamic study of sorafenib (S), a multi-targeted kinase inhibitor in combination with temsirolimus (T), an mTOR inhibitor in patients with advanced solid malignancies. J. Clin. Oncol. 2007;25 abstract 3512.</Citation>
        </Reference>
        <Reference>
          <Citation>Patel P.H., Senico P.L., Curiel R.E., Motzer R.J. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma. Clin. Genitourin. Cancer. 2009;7:24–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3740755</ArticleId>
            <ArticleId IdType="pubmed">19213664</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Houghton P. Targeting the IGF-1/mTOR pathway. Second AACR Centennial Conference on Translational Cancer Medicine; Monterey, CA, USA. 20–23 July 2008; Washington DC, Philadelphia, USA: AACR; 2008.  Abstract number PL05-03.</Citation>
        </Reference>
        <Reference>
          <Citation>Kurmasheva R.T., Easton J.B., Houghton P.J. Combined targeting of mTOR and the insulin-like growth factor pathway. ASCO Educ. Book 2008. 2008:460–464.</Citation>
        </Reference>
        <Reference>
          <Citation>Lasithiotakis K.G., Sinnberg T.W., Schittek B., Flaherty K.T., Kulms D., Maczey E., Garbe C., Meier F.E. Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells. J. Invest. Dermatol. 2008;128:2013–2023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18323781</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McDaid H.M., Legrier M., Yang C.H., Yan H.G., Lopez-Barcons L., Keller S.M., Horwitz S.B. Combined MEK and mTOR suppression is synergistic in human NSCLC and is mediated via inhibition of protein translation. J. Clin. Oncol. 2007;25 abstract 10615.</Citation>
        </Reference>
        <Reference>
          <Citation>Molhoek K.R., Brautigan D.L., Slingluff C.L., Jr. Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J. Transl. Med. 2005;3 doi: 10.1186/1479-5876-3-39..</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1479-5876-3-39.</ArticleId>
            <ArticleId IdType="pmc">PMC1289294</ArticleId>
            <ArticleId IdType="pubmed">16255777</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Romano M.F., Avellino R., Petrella A., Bisogni R., Romano S., Venuta S. Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur. J. Cancer. 2004;40:2829–2836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">15571967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Werzowa J., Cejka D., Fuereder T., Dekrout B., Thallinger C., Pehamberger H., Wacheck V., Pratscher B. Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. Br. J. Dermatol. 2009;160:955–964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">19120326</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thallinger C., Poeppl W., Pratscher B., Mayerhofer M., Valent P., Tappeiner G., Joukhadar C. CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model. Pharmacology. 2007;79:207–213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17377418</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eberle J., Kurbanov B.M., Hossini A.M., Trefzer U., Fecker L.F. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist. Updat. 2007;10:218–234.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18054518</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noh W.C., Mondesire W.H., Peng J., Jian W., Zhang H., Dong J., Mills G.B., Hung M.C., Meric-Bernstam F. Determinants of rapamycin sensitivity in breast cancer cells. Clin. Cancer Res. 2004;10:1013–1023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14871980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., Frost P., Gibbons J.J., Wu H., Sawyers C.L. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA. 2001;98:10314–10319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC56958</ArticleId>
            <ArticleId IdType="pubmed">11504908</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu K., Toral-Barza L., Discafani C., Zhang W.G., Skotnicki J., Frost P., Gibbons J.J. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr. Relat. Cancer. 2001;8:249–258.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11566616</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cloughesy T.F., Yoshimoto K., Nghiemphu P., Brown K., Dang J., Zhu S., Hsueh T., Chen Y., Wang W., Youngkin D., et al.  Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008;5 doi: 10.1371/journal.pmed.0050008..</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pmed.0050008.</ArticleId>
            <ArticleId IdType="pmc">PMC2211560</ArticleId>
            <ArticleId IdType="pubmed">18215105</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
